Phaseline

Targets › ASS1

ASS1 (Argininosuccinate synthase): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Gastroenterology, Oncology, Metabolic and endocrine; next expected readout Feb 2027.

One of the enzymes of the urea cycle, the metabolic pathway transforming neurotoxic amonia produced by protein catabolism into inocuous urea in the liver of ureotelic animals. Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP and together with ASL it is responsible for the biosynthesis of arginine in most body tissues. (UniProt, P00966)

Open in Phaseline: the race on ASS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Polaris GroupADI-PEG 20
Argininosuccinate synthase 1 (ASS1) depletion via pegylated arginine deiminase
ASS1Phase 3Hepatocellular Carcinoma; Glioblastoma Multiforme (GBM); Nonalcoholic Steatohepatitis (NASH); Prostate CancerFeb 2027
Rebecca Ahrens-NicklasLNP.UCD.ABE
adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge
CPS1, OTC, ASS1, ASL, ARG1Phase 1Urea Cycle DisordersSep 2028

Conditions

Hepatocellular Carcinoma (1) Glioblastoma Multiforme (GBM) (1) Nonalcoholic Steatohepatitis (NASH) (1) Prostate Cancer (1) Urea Cycle Disorders (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

Polaris Group (1) Rebecca Ahrens-Nicklas (1)

Related targets

CPS1 (1) OTC (1) ASL (1) ARG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.